Two years ago, when I started incorporating peptide protocols into my practice, and my own use, the conversations I had with patients required a lot of groundwork. Most people had never heard of BPC-157 or GHK-Cu or MOTS-C. The ones who had usually found out about them through a biohacking podcast or an Instagram post, and they had a mixture of genuine curiosity and reasonable skepticism about what these compounds actually were and whether they were legitimate medicine or expensive supplements with good marketing.

‍

That conversation has changed considerably. Peptides are now being discussed in mainstream news coverage, in congressional letters, and on some of the most listened-to podcasts in the world. The regulatory environment around them is actively shifting in real time. And the questions I am getting from patients, potential patients, and colleagues have become both more frequent and more sophisticated.

‍

This post is my attempt to give you a genuinely clear picture: what peptides actually are, where they came from scientifically, how they ended up in the regulatory gray zone, and what the current moment in Washington means for anyone who is already using them or thinking about it. At the end I will tell you what I can offer as a physician who has been working in this space for two years and who is glad to have this conversation with anyone who wants to have it.

‍

What peptides actually are

‍

The word peptide simply means a short chain of amino acids. Amino acids are the building blocks of proteins, and a peptide is essentially a small protein, typically between 2 and 50 amino acids long. Your body makes thousands of them naturally. Hormones like insulin and oxytocin are peptides. Growth hormone itself is a peptide. The GLP-1 molecules at the center of the tirzepatide and semaglutide revolution are peptides. In that sense, peptide therapy is not a radical departure from conventional medicine. It is an extension of something medicine has been doing for a long time, using the body's own molecular signaling language to produce targeted biological effects.

‍

What distinguishes the class of peptides that have become central to longevity and regenerative medicine is that most of them are not naturally occurring hormones but rather synthetic sequences, sometimes derived from naturally occurring proteins, that have been designed or discovered to produce specific physiological effects. BPC-157, for example, is a synthetic pentadecapeptide derived from a protein found in gastric juice. It does not exist in this exact form in nature, but its component sequence appears to exert potent tissue-healing, anti-inflammatory, and neuroprotective effects through multiple receptor pathways. SS-31, which I have used for mitochondrial support, was specifically engineered to target cardiolipin on the inner mitochondrial membrane. These are precision tools, not blunt instruments, surgical. 

‍

A brief history of peptide medicine

‍

The history of therapeutic peptides is actually much older than most people realize. Insulin was the first therapeutic peptide, isolated in 1921 and used clinically by 1922. That was over a century ago. Oxytocin was synthesized in 1953, earning its discoverers the Nobel Prize. ACTH, vasopressin, and a range of other naturally occurring peptide hormones entered clinical medicine throughout the mid-20th century.

‍

1921 - Insulin isolated by Banting and Best at the University of Toronto. The first therapeutic peptide enters clinical use the following year, saving the lives of patients who would otherwise have died of type 1 diabetes.

‍

1953 - Oxytocin synthesized by Vincent du Vigneaud, earning the Nobel Prize in Chemistry. Demonstrates for the first time that peptide hormones could be chemically synthesized and used therapeutically.

‍

1970s - Solid-phase peptide synthesis becomes widely available following Robert Merrifield's Nobel Prize-winning work. Makes it feasible to produce synthetic peptide sequences at scale, opening the door to therapeutic peptide discovery.

‍

1980s - Growth hormone secretagogues and early research peptides begin appearing in the scientific literature. Researchers begin exploring whether synthetic sequences can stimulate endogenous hormone production rather than simply replacing hormones directly.

‍

1990s - BPC-157 research begins at the University of Zagreb, initially studying its effects on gastric ulcer healing. The compound demonstrates unexpectedly broad tissue-healing effects across multiple organ systems.

‍

2000s - Peptides enter the longevity and performance medicine space through compounding pharmacies. Physicians working in anti-aging and functional medicine begin incorporating ipamorelin, CJC-1295, and other growth hormone-releasing peptides into clinical protocols.

‍

2010s - Rapid expansion of the peptide market through compounding pharmacies. GHK-Cu, thymosin alpha-1, thymosin beta-4, PT-141, and dozens of other sequences enter clinical use. The regulatory framework struggles to keep pace with the pace of discovery and adoption.

‍

2023 - FDA removes 19 peptides from consideration for the 503A Bulks List, designating them as Category 2 substances with significant safety risks, citing insufficient human safety data. The decision disrupts established clinical protocols and drives significant demand to unregulated gray market sources.

‍

2026 - HHS Secretary RFK Jr. signals reversal. The FDA announces advisory committee meetings for July 23 and 24 to evaluate whether seven of those peptides should be returned to the 503A Bulks List, allowing compounding pharmacies to produce them legally again.

‍

The peptides I use in practice

‍

Within the Vitality Architecture at Outlive Concierge Medicine, the compounds below form the core of my Phase 3 Apex toolkit. Some are classical peptides, short amino acid chains that speak the body's native cellular signaling language. Others, like methylene blue, are small molecules that operate on overlapping biological pathways and belong in the same clinical conversation. All are prescribed through licensed 503A compounding pharmacies under pharmaceutical-grade sourcing standards.

‍

TISSUE REPAIR AND GUT HEALTH

‍

BPC-157

TISSUE REPAIR

‍

Body Protection Compound 157 is a synthetic pentadecapeptide derived from a sequence found in gastric juice. It has the most extensive research literature of any compound in this class, with studies demonstrating accelerated healing of tendons, ligaments, muscle, bone, and gut mucosa. It also exerts meaningful anti-inflammatory and neuroprotective effects through multiple receptor pathways. It is one of the seven peptides currently under FDA advisory committee review for return to the 503A Bulks List.

‍

KPV

ANTI-INFLAMMATORY

‍

A tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone, KPV has potent anti-inflammatory effects that are particularly well characterized in the gut. It works by inhibiting NF-kB activation and reducing pro-inflammatory cytokine production. It is used in my practice for patients with gut permeability, inflammatory bowel conditions, and systemic inflammation where gut-origin inflammation appears to be a primary driver. The KPV/BPC-157 combination leverages complementary anti-inflammatory and tissue-repair mechanisms simultaneously.

‍

SLEEP AND RECOVERY

‍

DSIP

SLEEP ARCHITECTURE

‍

Delta Sleep-Inducing Peptide is a neuropeptide that promotes slow-wave, or delta, sleep, the deepest and most physiologically restorative stage of the sleep cycle. It was first isolated in rabbit cerebral venous blood in 1977 and has been studied for its effects on sleep architecture, stress hormone regulation, and pain modulation. For patients with sleep architecture disruption, particularly the suppression of deep sleep that is a central component of what I describe as the Vegas Tax, DSIP offers a physiologically targeted approach that works through different pathways than conventional sleep aids.

‍

METABOLIC OPTIMIZATION AND BODY COMPOSITION

‍

AOD-9604

METABOLIC

‍

AOD-9604 is a modified fragment of human growth hormone, specifically the region responsible for its lipolytic, or fat-burning, effects, without the growth-promoting or blood glucose-elevating effects of full growth hormone. It stimulates fat breakdown and inhibits fat formation through mechanisms that appear to involve beta-3 adrenergic receptors. It has been the subject of human clinical trials for obesity and has a documented safety profile superior to that of full growth hormone in this application. It is used in my practice as part of body composition and metabolic optimization protocols.

‍

MOTS-c

METABOLIC AND LONGEVITY

‍

MOTS-c is a mitochondrial-derived peptide encoded within the mitochondrial genome itself, making it one of the most biologically fundamental compounds in the longevity medicine toolkit. It functions as a metabolic regulator, activating AMPK signaling, improving insulin sensitivity, enhancing mitochondrial function, and demonstrating anti-aging effects in animal studies including extended lifespan. It declines with age and with metabolic dysfunction, making its restoration particularly relevant for patients with insulin resistance or significant mitochondrial decline.

‍

LONGEVITY AND EPIGENETIC REGULATION

‍

Epithalon

EPIGENETIC LONGEVITY

‍

Epithalon is a synthetic tetrapeptide originally developed in the 1980s by the St. Petersburg Institute of Bioregulation and Gerontology in Russia, where it has the most extensive human longevity research of any peptide in this class. It stimulates telomerase activity, promoting telomere elongation and slowing one of the core molecular clocks of cellular aging. It has demonstrated lifespan extension in multiple animal models, tumor suppression effects, and normalization of circadian rhythm and melatonin secretion. It represents the most direct available intervention on telomere biology outside of gene therapy.

‍

COGNITIVE ENHANCEMENT AND NEUROPROTECTION

‍

Selank

ANXIOLYTIC AND NOOTROPIC

‍

Selank is a synthetic heptapeptide analog of tuftsin developed at the Institute of Molecular Genetics in Russia, where it has been approved as a pharmaceutical anxiolytic. It exerts anxiolytic effects without sedation or dependence, modulates GABA and serotonin systems, increases BDNF expression, and has demonstrated cognitive-enhancing and immune-modulating properties in clinical studies. Unlike benzodiazepines, it does not produce tolerance or withdrawal. It is delivered intranasally for direct access to the central nervous system via the olfactory route, bypassing the blood-brain barrier.

‍

Semax

NEUROPROTECTION AND FOCUS

‍

Semax is a synthetic heptapeptide derived from ACTH, developed in Russia and approved there for the treatment of stroke, TIA, and cognitive impairment. It is one of the most studied nootropic peptides in existence, with over 40 years of Russian clinical research behind it. It significantly upregulates BDNF, the primary neuronal growth factor, increases dopaminergic and serotonergic activity, and produces measurable improvements in attention, memory consolidation, and stress resilience. Like Selank, it is delivered intranasally and acts rapidly on central nervous system targets.

‍

Dihexa

COGNITIVE REPAIR

‍

Dihexa is a small peptide derived from angiotensin IV, developed by researchers at Washington State University. It is arguably the most potent known stimulator of synaptogenesis, the formation of new synaptic connections, with studies showing it is approximately ten million times more potent than BDNF at promoting synapse formation in hippocampal tissue. It has demonstrated reversal of cognitive deficits in animal models of Alzheimer's disease and traumatic brain injury. It sits at the frontier of what cognitive medicine can currently offer and is used selectively in patients with significant cognitive decline concerns or as a peak cognitive performance intervention.

‍

CELLULAR ENERGY AND MITOCHONDRIAL SUPPORT

‍

NAD+ 

MITOCHONDRIAL AND EPIGENETIC

‍

NAD+, or nicotinamide adenine dinucleotide, is not a peptide but belongs in this section as one of the most important molecules in the longevity medicine toolkit. It is the primary fuel source for sirtuin enzymes, the epigenetic maintenance proteins that sit at the center of David Sinclair's Information Theory of Aging. NAD+ declines approximately 50% by age 50, directly impairing cellular repair, mitochondrial function, and epigenetic maintenance.

‍

Methylene Blue

MITOCHONDRIAL ELECTRON TRANSPORT

‍

Methylene blue is a century-old compound with a remarkably modern mechanistic story. It acts as an alternative electron carrier in the mitochondrial electron transport chain, bypassing dysfunctional complexes to improve ATP production and reduce reactive oxygen species generation. At low hormetic doses it activates the Nrf2 pathway, upregulating the body's endogenous antioxidant systems. It also weakly inhibits MAO-A and acetylcholinesterase, producing nootropic effects on mood and cognition. It has one of the most pronounced inverted-U dose-response curves of any compound I use, meaning precise dosing is essential to achieve benefit rather than paradoxical impairment.

‍

Tesofensine

METABOLIC AND APPETITE REGULATION

‍

Tesofensine is a triple monoamine reuptake inhibitor, blocking the reuptake of serotonin, dopamine, and noradrenaline, originally developed for Parkinson's and Alzheimer's disease before its significant weight loss effects were identified in clinical trials. It produces appetite suppression and modest increases in resting metabolic rate through central nervous system mechanisms distinct from GLP-1 pathways. It is used in my practice selectively for patients who have not responded adequately to GLP-1 therapy alone or who have specific appetite dysregulation patterns that respond better to monoaminergic intervention. It requires careful patient selection and monitoring given its CNS activity profile.

‍

A note on sourcing: every compound listed above is prescribed through licensed 503A compounding pharmacies operating under pharmaceutical-grade ingredient standards. I do not recommend or endorse gray-market or research-chemical sources for any of these compounds. The sourcing question is as important as the molecule itself, and I am glad to discuss my specific pharmacy relationships with any patient considering these protocols.

‍

The regulatory story: how we got here

‍

To understand the current moment, you need to understand the legal framework governing compounded peptides. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies can prepare customized medications for individual patients under a physician's prescription, as long as the bulk drug substances they use meet certain criteria. The FDA maintains a 503A Bulks List that designates which bulk substances compounders are explicitly authorized to use.

‍

For years, most of the peptides I have described above were produced by compounding pharmacies operating under an informal understanding that they were permitted because they had not been explicitly prohibited. In September 2023, the Biden administration's FDA moved to formalize that status in the wrong direction, designating 19 peptides as Category 2 substances, meaning the FDA had identified significant safety risks and would consider enforcement action against compounders producing them. The rationale was largely the absence of sufficient human safety data.

‍

The practical effect was significant. Established compounding pharmacies that had been producing pharmaceutical-grade peptides under sterile conditions stopped doing so, or reduced their operations substantially. Physicians who had built clinical protocols around these compounds faced supply disruptions. And the patients who still wanted access increasingly turned to unregulated online sources, often gray-market powders of unknown purity and origin. The safety rationale for the restriction had inadvertently produced a worse safety outcome.

‍

CURRENT REGULATORY UPDATE — APRIL 2026

‍

In February 2026, HHS Secretary Robert F. Kennedy Jr. said he expected the FDA to take action within weeks to make roughly 14 peptides more accessible. He characterized the 2023 restrictions as illegal overreach.

‍

On April 15, 2026, the FDA announced it was removing 12 of those peptides from the Category 2 restricted list and scheduling a two-day advisory committee meeting for July 23 and 24, 2026, to formally evaluate whether seven peptides, including BPC-157, should be added to the 503A Bulks List, which would allow compounding pharmacies to produce them again without fear of enforcement action.

‍

Kennedy described the move as "long-overdue action to restore science, accountability, and the rule of law," and stated that the reclassification "begins to restore regulated access and will immediately begin shifting demand away from the black market." Even if the advisory committee votes in favor, compounding pharmacies will need time to ramp up production. The full regulatory process, including rule-making and publication, could take months beyond the July meeting. But the direction of travel is now clear.

‍

My view on this is straightforward. The gray market that developed in the wake of the 2023 restrictions was a genuine safety problem. Unregulated sources selling peptide powders online, often sourced from overseas manufacturers with no FDA oversight, represent a real risk that pharmaceutical-grade compounding from licensed pharmacies does not. Bringing these compounds back into a regulated, physician-supervised compounding framework is the better outcome for patients. It does not resolve every scientific question about efficacy or long-term safety, and I want to be honest that the clinical trial evidence base for many of these peptides remains limited. But it moves the conversation from the back alley to the clinic, where it belongs.

‍

The source question: why it matters enormously

‍

One of the most important things I tell every patient who asks about peptides is that the compound itself is only part of the picture. The source matters as much as the molecule. A pharmaceutical-grade BPC-157 produced by a licensed 503A compounding pharmacy under sterile conditions and USP-grade ingredient requirements is a fundamentally different product from a vial ordered from a research chemicals website, even if the label says the same thing.

‍

Peptides are relatively simple molecules that are easy to synthesize, which makes them easy to fake, dilute, or contaminate. The compounding pharmacies I work with are licensed in Nevada and in the states where my patients reside, they source active pharmaceutical ingredients from FDA-registered domestic manufacturers, and they operate under sterile compounding standards. That supply chain is what makes a prescription peptide protocol a medical intervention rather than a gamble.

‍

This is one of the reasons I believe physician oversight of peptide therapy matters. Not because patients cannot be trusted to make their own decisions, but because navigating the source question, the dosing question, the cycling question, and the interaction question competently requires clinical knowledge that takes time to develop. I have spent two years developing it. I am happy to put that to work for my patients.

‍

What I can offer you: Physician-guided peptide protocols at OCM

‍

Patient selection and baseline assessment: Not every patient is an appropriate candidate for every peptide, and the right starting point depends on your specific goals, your baseline labs, your current medications, and your phase in the Vitality Architecture. I do a thorough clinical assessment before recommending any peptide protocol.

‍

Protocol design: Dosing, cycling, administration route, injection technique, and the sequencing of multiple peptides when used in combination all require clinical judgment. The one-size-fits-all protocols circulating online are a starting point, not a prescription. I design protocols specific to you.

‍

Pharmaceutical-grade sourcing: All peptides I prescribe are obtained through licensed 503A compounding pharmacies that meet my sourcing standards. I do not recommend or endorse any gray-market or research-chemical sources, and I am happy to discuss the specific pharmacies I work with during a consultation.

‍

Injection training: For subcutaneous peptides, proper injection technique matters for both efficacy and comfort. I provide detailed written dosing instructions with every protocol and am available for telehealth walk-throughs of injection procedure for new patients.

‍

Monitoring and response tracking: Peptide protocols work best when they are part of a broader longevity framework that includes baseline and follow-up labs, HRV tracking, body composition monitoring, and regular clinical review. The Vitality Architecture provides exactly that structure.

‍

Honest conversation about the evidence: I will always tell you what the clinical evidence actually supports and where we are working at the frontier of emerging medicine rather than established protocol. Some of what I do in Phase 3 is informed by biological plausibility and early research rather than large randomized trials. You deserve to know that, and I think most patients who are drawn to this space already understand it.

‍

I have been studying peptide science for over two years and prescribing peptide protocols for the same period. I am glad the conversation is becoming more mainstream and legitimate. These are genuinely fascinating compounds with real clinical potential, and the physician-supervised, pharmaceutical-grade, protocol-driven approach to them is the right one.

‍

If you are curious about whether peptide therapy has a place in your own health strategy, I would be glad to talk about it. Book a free consultation and let us start with where you actually are biologically, and work forward from there.

‍

Outlive Concierge Medicine offers physician-supervised peptide protocols as part of the Phase 3 Apex tier of the Vitality Architecture. If you are in Las Vegas, Summerlin, or Henderson, or anywhere in Nevada or Arizona via telehealth, book a free consultation to discuss whether peptide therapy is appropriate for you.

‍